| B02BD04 |
Coagulation factor IX |
Alprolix |
Powder and solvent for solution for injection |
500 |
IU |
1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 infusion set + 2 swabs + 2 plasters + 1 gauze |
Swedish Orphan Biovitrum AB, Швеция |
1 |
IU |
1138.56 |
- |
2.25712 |
1128.56 |
100% |
1128.56 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
НСР-14169/13.10.2017; КП-31/06.03.2019 и НСР-17515/13.12.2018 |
02.04.2019 |
|
|
Активен |
15905 |
| B02BD04 |
Coagulation factor IX |
Alprolix |
Powder and solvent for solution for injection |
250 |
IU |
1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 infusion set + 2 swabs + 2 plasters + 1 gauze |
Swedish Orphan Biovitrum AB, Швеция |
1 |
IU |
575.28 |
- |
2.25712 |
564.28 |
100% |
564.28 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
НСР-14169/13.10.2017; КП-31/06.03.2019 и НСР-17527/13.12.2018 |
02.04.2019 |
|
|
Активен |
15904 |
| B02BD04 |
Coagulation factor IX |
Alprolix |
Powder and solvent for solution for injection |
2000 |
IU |
1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 infusion set + 2 swabs + 2 plasters + 1 gauze |
Swedish Orphan Biovitrum AB, Швеция |
1 |
IU |
4518.23 |
- |
2.25712 |
4514.24 |
100% |
4514.24 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
НСР-14169/13.10.2017; КП-31/06.03.2019 и НСР-17526/13.12.2018 |
02.04.2019 |
|
|
Активен |
15907 |
| B02BD04 |
Coagulation factor IX |
Alprolix |
Powder and solvent for solution for injection |
1000 |
IU |
1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 infusion set + 2 swabs + 2 plasters + 1 gauze |
Swedish Orphan Biovitrum AB, Швеция |
1 |
IU |
2265.12 |
- |
2.25712 |
2257.12 |
100% |
2257.12 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
НСР-14169/13.10.2017; КП-31/06.03.2019 и НСР-17525/13.12.2018 |
02.04.2019 |
|
|
Активен |
15906 |
| B02BD04 |
Coagulation factor IX |
Alprolix |
Powder and solvent for solution for injection |
3000 |
IU |
1 vial + 1 pre-filled syringe + 1 plunger rod + 1 vial adapter + 1 infusion set + 2 swabs + 2 plasters + 1 gauze |
Swedish Orphan Biovitrum AB, Швеция |
1 |
IU |
6771.35 |
- |
2.25712 |
6771.35 |
100% |
6771.35 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
НСР-14169/13.10.2017; КП-31/06.03.2019 и НСР-17528/13.12.2018 |
02.04.2019 |
|
|
Активен |
15908 |
| B02BD04 |
Coagulation factor IX (nonacog alfa) |
B02BD04 Coagulation factor IX (nonacog alfa) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD04 |
Coagulation factor IX (nonacog alfa) |
BeneFIX |
Powder and solvent for solution for injection |
500 |
IU |
1 vial powder + 1 pre-filled syringe solvent 5 ml + 1 injection set |
Pfizer Europe MA EEIG, Белгия |
450 |
IU |
560.38 |
- |
504.84685 |
560.38 |
100% |
560.38 |
За експертиза по чл.78 т.2 от ЗЗО |
D67 |
HCР-19/31.05.2013 г.; НСР-14847/18.01.2018; НСР-16545/17.08.2018 (предварително изпъленение); НСР-17316/22.11.2018; НСР-18670/20.05.2019 |
02.07.2019 |
|
|
Активен |
1849 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
B02BD06 Coagulation factor VIII, Factor von Willebrand |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
Wilate 1000 |
Powder and solvent for solution for injection |
1000 |
IU |
1 |
Octapharma (IP) Ltd., Обединено Кралство |
7200 |
IU |
938.96 |
- |
6760.51221 |
938.96 |
100% |
938.96 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D68.0 |
НСР-1794/25.11.2013; НСР-5155/27.11.2014; НСР-6059/16.04.2015 |
16.05.2015 |
|
|
Заличен |
3419 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
WILATE 450 powder for solution for injection 450 IU x 1 |
Powder and solvent for solution for injection |
450 |
IU |
1 |
Octapharma (IP) Ltd., Обединено Кралство |
7200 |
IU |
962.53 |
- |
6845.75977 |
427.86 |
100% |
427.86 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D68.0 |
№ 43/ 07.01.2010; № 140/ 24.01.2011; № 178/ 22.06.2011; НСР-3931/30.06.2014 |
02.08.2014 |
08.09.2012 |
|
Заличен |
723 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
Wilate 500 |
Powder and solvent for solution for injection |
500 |
IU |
1 |
Octapharma (IP) SPRL, Белгия |
7200 |
IU |
471.14 |
- |
6730.57143 |
471.14 |
100% |
471.14 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D68.0 |
НСР-1794/25.11.2013; НСР-5154/27.11.2014; КП-394/06.11.2015 и НСР-7055/03.09.2015; НСР-10295/15.09.2016; КП-142/08.11.2017 и НСР-13402/04.08.2017; АССГ № 481/19.01.2018 и НСР-10295/15.09.2016; НСР-17635/20.12.2018 |
02.02.2019 |
|
|
Активен |
3418 |
| B02BD06 |
Coagulation factor VIII, Factor von Willebrand |
WILATE 900 powder for solution for injection 900 IU x 1 |
Powder and solvent for solution for injection |
900 |
IU |
1 |
Octapharma (IP) Ltd., Обединено Кралство |
7200 |
IU |
856.92 |
- |
6845.75977 |
855.72 |
100% |
855.72 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D68.0 |
№ 43/ 07.01.2010; № 140/ 24.01.2011; № 178/ 22.06.2011; КЦРР-2256/11.02.2013 и КП-4/05.02.2014; НСР-3931/30.06.2014 |
02.08.2014 |
08.09.2012 |
|
Заличен |
2556 |
| B02BD08 |
Eptacog alfa (activated) |
B02BD08 Eptacog alfa (activated) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
2 mg (100KIU) |
|
1 vial + 1 vial |
Novo Nordisk A/S, Дания |
2500 |
KIU |
2590.99 |
- |
64774.75 |
2590.99 |
100% |
2590.99 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D67,D68.2 |
№ 179/ 22.06.2011; ; КЦРР-1385/05.09.2012 г.; НСР-515/11.07.2013; НСР-3328/24.04.2014.; НСР-7854/15.01.2016.; НСР-15693/17.05.2018 |
02.06.2018 |
08.09.2012 |
|
Заличен |
2734 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
5 mg (250 KIU) |
|
1 vial + 1 syringe + 1 vial adapter |
Novo Nordisk A/S, Дания |
2500 |
KIU |
6611.75 |
- |
64283.75 |
6428.38 |
100% |
6428.38 |
За експертиза по чл. 78, т.2 от ЗЗО |
D66,D67,D68.2 |
НСР-11317/30.12.2016 г.; НСР-18140/07.03.2019 |
02.04.2019 |
|
|
Активен |
15558 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven |
Powder and solvent for solution for injection |
2 mg (100 KIU) |
|
1 vial + 1 syringe + 1 vial adapter |
Novo Nordisk A/S, Дания |
2500 |
KIU |
2571.35 |
- |
64283.75 |
2571.35 |
100% |
2571.35 |
За експертиза по чл. 78, т.2 от ЗЗО |
D66,D67,D68.2 |
НСР-11317/30.12.2016; НСР-18043/28.02.2019 предварително изпълнение |
02.03.2019 |
|
|
Активен |
15557 |
| B02BD08 |
Eptacog alfa (activated) |
NovoSeven 2.4 mg |
Powder and solvent for solution for injection |
120 |
KIU |
1 |
Novo Nordisk A/S, Дания |
2500 |
TIU |
3007 |
- |
62645.83203 |
3007 |
100% |
3007 |
За експертиза по чл.78 т.2 от ЗЗО |
D66,D67,D68.2 |
№ 140/ 24.01.2011; № 151/ 14.03.2011; КЦРР-982/16.07.2012 |
14.08.2012 |
08.09.2012 |
|
Заличен |
676 |
| B02BX05 |
Eltrombopag |
B02BX05 Eltrombopag |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B02BX05 |
Eltrombopag |
REVOLADE |
Film coated tablet |
50 |
mg |
28 |
Novartis Europharm Limited, Обединено Кралство |
1 |
mg |
3891.18 |
- |
2.96276 |
4147.87 |
100% |
4147.87 |
За експертиза по чл.78 т.2 от ЗЗО |
D69.3 |
№ 208/ 04.11.2011; КЦРР-196/08.02.2012 г.; HCР-306/28.06.2013; НСР-3385/29.04.2014 |
02.06.2014 |
08.09.2012 |
|
Заличен |
3232 |
| B02BX05 |
Eltrombopag |
REVOLADE |
Film coated tablet |
25 |
mg |
28 |
Novartis Europharm Limited, Обединено Кралство |
1 |
mg |
1928.93 |
- |
2.96276 |
2073.94 |
100% |
2073.94 |
За експертиза по чл.78 т.2 от ЗЗО |
D69.3 |
№ 208/ 04.11.2011; КЦРР-196/08.02.2012 г.; HCР-857/09.08.2013; НСР-3384/29.04.2014 |
02.06.2014 |
08.09.2012 |
|
Заличен |
3568 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
MALTOFER |
Syrup |
10 mg/ml - 150 ml |
mg |
1 |
VIFOR France, SA, Франция |
1 |
mg |
- |
7.01 |
0.00467 |
7.01 |
25% |
1.75 |
|
D50.0,N18.0,N18.8 |
№ 20/15,07,2009
№40/27.08.2009; НСР-352/03.07.2013; НСР-4554/03.09.2014 |
02.10.2014 |
08.09.2012 |
|
Заличен |
2191 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
MALTOFER DROPS |
|
50 mg/ml - 30 ml |
mg |
1 |
VIFOR France, SA, Франция |
1 |
mg |
- |
5.84 |
0.00389 |
5.84 |
25% |
1.46 |
|
D50.0,N18.0,N18.8 |
№ 20/15,07,2009
№40/27.08.2009; НСР-355/03.07.201; НСР-4132/23.07.2014; НСР-4552/03.09.2014 |
02.10.2014 |
08.09.2012 |
|
Заличен |
3045 |
| B03AB04 |
Iron (III) - hydroxide polymaltose complex |
B03AB04 Iron (III) - hydroxide polymaltose complex |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|